ArticleTherapeutic delivery2017
Challenges in realizing selectivity for nanoparticle biodistribution and clearance: lessons from gold nanoparticles.
Article in Therapeutic delivery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 1 synthesis or guideline pooled it, 135 citations in OpenAlex.
- Meta-Analysis of Nanoparticle Distribution in Tumors and Major Organs in Tumor-Bearing Mice.ACS nano · 2023Pooled it
- Visualizing Metabolism: Lipid-Based Raman Nanoreporters as an Enabling Platform for Metabolic Imaging and Precision Medicine.ACS nano medicine · 2026Review
- Gold Nanoparticle-Based Precision Medicine Strategies for Glioblastoma: Current Biomedical Applications and Future Outlook.Molecules (Basel, Switzerland) · 2026Review
- Theranostic Potentials of Metallic Nanoparticles in Thyroid Diseases: Challenges and Prospects.International journal of nanomedicine · 2026Review
- Progress in the Application of Nanomaterials in Tumor Treatment.Biomedicines · 2025Review
- Medical importance and pharmacokinetics of gold nanoparticles in the human body.Molecular cancer · 2025Review
- Influence of PEG Molecular Weight on Washout Resistance and Deposition Efficiency of Magnetoresponsive Nanoclusters Under Pulsatile Flow for Magnetic Drug Targeting.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Effect of Size and Targeting Agent on Biodistribution of Polystyrene Nanoparticles in Apolipoprotein E Knock-Out and Wild-Type Mice.Diagnostics (Basel, Switzerland) · 2025Article
- Nucleic acid aptamers in orthopedic diseases: promising therapeutic agents for bone disorders.Bone research · 2025Review
- Research advancements in nanoparticles and cell-based drug delivery systems for the targeted killing of cancer cells.Oncology research · 2025Review
- Nanobodies Outperform Antibodies - Rapid Functionalization with Equal In Vivo Targeting Properties.Advanced materials (Deerfield Beach, Fla.) · 2024Article
- Plug-and-play nucleic acid-mediated multimerization of biparatopic nanobodies for molecular imaging.Molecular therapy. Nucleic acids · 2024Article
- Autophagy and mitophagy as potential therapeutic targets in diabetic heart condition: Harnessing the power of nanotheranostics.Asian journal of pharmaceutical sciences · 2024Review
- A Step Forward for the Treatment of Localized Prostate Cancer Using Gold Nanoparticles Combined with Laser Irradiation.International journal of molecular sciences · 2024Article
- Integrating Nanotechnological Advancements of Disease-Modifying Anti-Rheumatic Drugs into Rheumatoid Arthritis Management.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Liver-Targeting Nanoplatforms for the Induction of Immune Tolerance.Nanomaterials (Basel, Switzerland) · 2023Review
- Review
- Improvement of the Effectiveness of HER2+ Cancer Therapy by Use of Doxorubicin and Trastuzumab Modified Radioactive Gold Nanoparticles.Molecular pharmaceutics · 2023Article
- Safety of Gold Nanoparticles: From In Vitro to In Vivo Testing Array Checklist.Pharmaceutics · 2023Article
- Polymeric encapsulation of a ruthenium(ii) polypyridyl complex: from synthesis toChemical science · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The field of nanomedicine has received much attention for its potential to allow for targeted identification and treatment of tumors, while sparing healthy tissue. This promise has yet to be clinically realized; instead nanomedicine has translated into clinical benefit via formulations that improve the pharmacokinetics and toxicity profiles of toxic chemotherapeutic agents. In this perspective, we highlight that several of the defining strategies for using nanoparticles intravenously to target solid tumors have limited supporting data in animal studies. Namely, it does not appear that reducing macrophage (and other cell type) uptake in vitro leads to better biodistribution in vivo, nor does increasing blood circulation time nor active targeting. We suggest instead that the coming decade will primarily see nanoparticles impact immunotherapy and local/pseudolocal cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.